Please ensure Javascript is enabled for purposes of website accessibility

Why BioNTech Stock Is Falling Today

By Prosper Junior Bakiny – Sep 3, 2020 at 1:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Markets are down today, and BioNTech is dropping along with them.

What happened?

Shares of BioNTech (BNTX -1.27%) are down by 4.6% as of 1:34 p.m. EDT on Thursday, despite the company not reporting any news. However, with all three major U.S. market indexes dropping today (as of this writing), it is safe to assume that shares of the German biotech are being dragged down along with the broader market. 

So what

Earlier this year, BioNTech teamed up with pharma giant Pfizer to develop a vaccine for the novel coronavirus. The two companies' lead candidate, BNT162b2, is currently undergoing a phase 2b/3 clinical study. The trial will involve 30,000 participants aged 18 to 85. Its primary endpoints will be the prevention of COVID-19 in patients who have yet to be infected by the SARS-CoV-2 virus, as well as the prevention of the disease whether or not an individual has already contracted the virus. 

Man holding his head in panic with a downward-pointing graph in the background

Image source: Getty Images.

Thanks to these efforts, BioNTech's stock surged during the first half of the year, but the company has been giving up much of these gains over the past month and a half (or so). Since July 22, BioNTech's stock is down by more than 40%. Today's market sell-off probably exacerbated this situation for the biotech company.

Now what

BioNTech has no products on the market at the moment, and its near-term prospects hinge on its COVID-19 programs. That is not necessarily a bad thing considering its vaccine candidate is widely regarded as one of the leaders in the race. BioNTech and Pfizer plan on releasing some data on the ongoing phase 2b/3 clinical study for BNT162b2 as early as October. Also, the two companies have signed deals with the U.K. and U.S. governments (among others) to deliver millions of doses of their vaccine, pending regulatory approval. Given these factors, BioNTech's stock could recover from its recent woes. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
BNTX
$128.35 (-1.27%) $-1.65

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.